Page 486 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

444 MEDICAMENTINDUISANT OUSTABILISANTDES COUPURES DE L'ADN

BIBLIOGRAPHIE
VECTORISATION, CIBLAGE
WARENIUS H.M. et al., Response of a high-glüroidàs&pp)rfafjshpur xenograft to
aniline mustard, Br. J. Cancer, 1982, 45, 27.
GAVERIAUX C., SDZ PSC 833, a non-immunosùp?&ssiveey[ospin analog, is a very
potent multidrug-resistance modifier, J Cell Pharacl,,_g9+,2, 225-234.
TWENTYMAN P.R., BLEEHEN N. M., Resistance modification by PSC-833, a novel non
immunosuppressive cyclosporin A, Eur. J. Cancer, 1991, 27, 1639-1642.
PEREZ-SOLER R. et al., Use of drug carriers to ameliorate the therapeutic index of
anthracycline antibiotics in Anthracycline antibiotics, new analogues, methods of deli-
very, and mechanisms of action, W. PRIEBE, Ed., ACS Symposium Series 574, ACS,
Washington, 1995, 300-319.
TRAIL P.A. et al., Site-directed delivery of anthracylcines for treatment of cancer, Drug
Development Research, 1995, 34, 196-209.
WATANABE T., Modulation of multidrug resistance by SDZ PSC 833 in leukemic and
solid-tumor-bearing mouse models, Jpn. J. Cancer Res., 1996, 87, 184-193.
DUBOWCHIK G.M., RADIA S., Monomethoxytrityl (MMT) as a versatile amine protecting
group for complex prodrugs of anticancercompounds sensitive to strong acids, bases
and nucleophiles, Tetrahedron Letters, 1997, 38, 5257-5260.
BOSSLET K et al., Elucidation of the mechanism enabling tumorselective prodrug mono-
therapy, Cancer Res., 1998, 58, 1195-2001.
DE GROOT F.M.H. et al., Synthesis and biological evaluation of novel prodrugs of anthra-
cyclines for selective activation by the tumor-associated protease plasmin, J. Med.
Chem., 1999, 42, 5277-5283.
DRUMMOND D.C. et al., Optimizing liposomes for delivery of chemotherapeutic agents
to solid tumors, Phamacol. Rev., 1999, 51, 691-743.
DUNCAN R., Polymer conjugales fortumourtargeting and intracytoplasmic delivery. The
EPR effect as a common gateway 7, PSTT, 1999, 2, 441-448.
HONG K. et al., Anti-HER2 immunoliposomes for targeted drug delivery in Anticancer
molecules, structure, function and design, Ed. Maruta H., Annals of the New York
Academy of Sciences, 1999, volume 886, New York 10024.
KLING J., The liposome marker's art : wrapping toxic drugs in lipid disguises, Modern
Drug Discovery, 1999, 41-49.
LEENDERS R. et al., Novel anthracycline-spacer-B-glucuronide,-B-glucoside, and B-
galactoside prodrugs for application in selective chemotherapy, Bioorg. Med. Chem.,
1999, 7, 1597-1610.
MELTON R. et al., The use of prodrugs in targeted anticancer therapies, S. T. P. Pharma
Sciences, 1999, 9, 13-33.
MILLS J.K., NEEDHAM D., Targeted drug delivery, Exp Ofin. Ther Patents, 1999,9, 1499-1513.
.
NICULESCU-DUVAZ I. et al., Self-immolative anthracycline prodrugs for suicide gene
therapy, J. Mead. Chem., 1999, 42, 2485-2489.
VASEY P.A. et al., Phase I clinical and pharmacokinetic study of PK1 N-(2-hydroxypro-
pyl)methacrylamide copolymer doxorubicin] : first member of a new class of chemo-
therapeutic agents - drug polymer conjugates, Clin. Cancer Res., 1999, 5, 83-94.